Wutah dodolan YoY sajrone 12 wulan kepungkur: senseibio.com (SNSE)

The year-over-year revenue dynamics for the last 12 months provided by the GURU.Markets system are based on the validation of the TMAb platform for T-cell stimulation for Sensei Biotherapeutics (SNSE). The value 0.00 serves as the current parameter for this process. Consequently, Sensei Biotherapeutics (SNSE) is developing ImmunoPhage to create anti-cancer vaccines, relying exclusively on its internal pipeline and academic partnerships without engaging in M&A transactions.
Sensei Biotherapeutics (SNSE) - rincian metrik lan laporan keuangan

Sensei Biotherapeutics (SNSE) is optimizing the development of cancer antibodies through AI automation and robotics. This indicator captures the daily change in trailing twelve-month revenue, measuring revenue growth rates in real time. The metric allows investors to assess the business's operational resilience and the impact of currency factors on capital. This analysis helps identify a slowdown in the company's expansion in a timely manner. The dynamics of these processes are clearly reflected in the trend of the LTM sales volume change.